(PRLeap.com) Aachen, Germany, 2 June 2025 - Grรผnenthal today announced the acquisition of the commercial rights to Cialisยฎ (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Grรผnenthal and Lilly will work together to transfer the manufacturing to Grรผnenthal's production site in Santiago, Chile, that will supply Cialisยฎ for Mexico, Brazil and Colombia moving forward. The transaction is expected to close in the third quarter of 2025, subject to the satisfaction of customary closing conditions. Grรผnenthal will finance the transaction using available liquidity. The financial terms of the transaction are not disclosed.
Cialisยฎ is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men . The acquisition will expand Grรผnenthal's Latin American Men's Health product portfolio.
"Executing on our strategy of targeted acquisitions, Cialisยฎ will expand our existing portfolio in the region and strengthen Grรผnenthal's Latin American business", says Gabriel Baertschi, CEO, Grรผnenthal. "In 2022, we acquired Nebidoยฎ, a long-acting treatment for testosterone deficiency, and with Cialisยฎ we can continue to serve our existing customer base and foster our growth in key Latin American markets."
Through the acquisition of Cialisยฎ, Grรผnenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability. Since 2017, Grรผnenthal has invested over ๏ฟฝ2 billion in the acquisition of established medicines, including Nebidoยฎ, the European rights to Crestorยฎ and Nexiumยฎ, as well as the global rights to Vimovoยฎ (excluding the U.S. and Japan), Qutenzaยฎ and Zomigยฎ (excluding Japan). In 2023, Grรผnenthal established Grรผnenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantikยฎ.
About Grรผnenthal
Grรผnenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grรผnenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grรผnenthal employed around 4,300 people and achieved revenues of ๏ฟฝ1.8 billion.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal
GET IN TOUCH
Maren Thurow
Grรผnenthal Group
+44 7917 196855
You can see the original version and more on PRLeap here: http://www.prleap.com/pr/305406/grunenthal-announces-acquisition-of-the-rights-to-cialisr-from-lilly-in-mexico-brazil-colombia
